Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Arteriocyte Recieves FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors 

 

Arteriocyte Recieves FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
January 31, 2013 - (PRNewswire) - "Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan® System technology in the treatment of thermal burn wounds." Read Full Press Release

 

Posted on 14-Feb-13 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: